National Graphite Corp. 是一家勘探公司,从事黄金、白银及相关矿物的勘探。公司总部位于北莱茵-威斯特法伦州杜塞尔多夫。该公司于2009年6月30日上市。该公司正在推进一种候选药物elafin的商业化开发,用于治疗术后炎症并发症。Elafin是一种人同源蛋白。公司主要在德国运营,与处于临床阶段的公司合作,开发用于治疗各种疾病、罕见病以及未满足医疗需求疾病的新型生物实体或新型治疗平台。Biotech Development Corp. 是该公司的子公司。截至2015年2月28日,该公司尚未产生任何收入。
NGRC stock price ended at $0.02 on 星期二, after dropping 50.00%
On the latest trading day Feb 10, 2026, the stock price of NGRC fell by 50.00%, dropping from $0.02 to $0.02. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.02 and a high of $0.02. On the latest trading day, the trading volume for NGRC decreased by 998 shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 899 shares were traded, with a market value of approximately $3.0M.